Novel small molecule inhibitors of Focal Adhesion Kinase (FAK)

Focal adhesions are cell junctions that act as mechanical linkages between the intracellular actin cytoskeleton of a live cell and the extracellular matrix (ECM). They have a wide functional scope. In this context Focal Adhesion Kinase (FAK) plays a pivotal role. FAK is often overexpressed in tumor cells and is partly responsible for the high tissue invasiveness of the infected cells. Now “small molecules” have been developed at the University of Konstanz, Germany, that interfere with the localization and thus with FAK functioning. Therefore, these molecules can be deployed in cancer treatment as well as in the prevention and treatment of restenosis via drug-eluting stents.
The novel FAK inhibitors are highly effective, cell-penetrating, easy to sterilize and can be produced through chemically defined synthesis.

Further information: PDF

Technologie-Lizenz-Büro (TLB) der Baden-Württembergischen Hochschulen GmbH
Phone: +49 (0)721/79 00 40

Contact
Dipl.-Biol. Marcus Lehnen, MBA

As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.